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Inherited primary arrhythmias, namely congenital long QT syndrome, Brugada syndrome
and catecholaminergic polymorphic ventricular tachycardia, account for a significant
proportion of sudden cardiac deaths in young and apparently healthy individuals. Genetic
testing plays an integral role in the diagnosis, risk-stratification and treatment of probands
and family members. It is increasingly obvious that collaborative efforts are required to
understand and manage these relatively rare but potentially lethal diseases. This article
aims to update readers on the recent developments in our knowledge of inherited ar-
rhythmias and to lay the foundation for a national synergistic effort to characterize them
in the Indian population.
Copyright ª 2013, Cardiological Society of India. All rights reserved.Inherited primary arrhythmia syndromes are electrical ab-
normalities of the heart caused by derangements in the
structure and function of the cardiac ion channels. Since a
majority of the primary arrhythmias are due to mutations in
the genes encoding the ion channels of the heart, namely Naþ,
Kþ and Caþþ channels, they are referred to as “cardiac ion
channelopathies”.1 These are typically monogenic disorders,
that is, disorders that follow a clear Mendelian pattern of in-
heritance, although for some of them amore complex pattern
emerges.2 They are most often inherited in an autosomal
dominant pattern, which explains the strong role for family
screening in the management of affected patients.3mail.com, p.chockalingam
2013, Cardiological SocietAutosomal recessive inheritance and the occurrence of de
novo mutations are also seen but less frequently.
Sudden cardiac death (SCD), defined as death from a car-
diac cause occurring shortly after the onset of symptoms, is
most often due to an organic cardiac abnormality, such as
coronary artery disease or structural heart disease. However,
death in young, active and previously healthy individuals with
no identifiable cause on autopsy, termed sudden arrhythmic
death syndrome (SADS), constitutes up to 5% of SCD in the
general population aged 16e64 years and almost 25e35% of
sudden deaths in the <40 years age group.4 When sudden
death of unknown aetiology occurs in a child <1 year of age, it@amc.uva.nl (P. Chockalingam).
y of India. All rights reserved.
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current annual incidence of about 50/100,000 in the United
States.4,5 Unravelling themystery surrounding SADS and SIDS
has been the focus of numerous research efforts recently. As a
result of this increased interest as well as the concurrent ad-
vances in the molecular, genetic, experimental and clinical
aspects of medicine, we have witnessed an exponential in-
crease in knowledge on the genetic background of SCD in the
recent past. Inherited arrhythmia syndromes play an integral
role in this ever-expanding realm of young unexpected deaths
and are currently implicated in about 20e35% of cases as
shown by post-mortem genetic testing, also termedmolecular
autopsy.6e8
The flow of ions into and out of the cardiac myocyte is so
delicately balanced that neither a loss nor a gain of the ionic
channel function is tolerated by the intricately functioning
electrical system of the heart. Based on whether the func-
tional derangement caused by the underlying genetic abnor-
mality is a decrease or an increase in ionic conduction, the
channelopathies are categorized as loss-of-function or a gain-
of-function channelopathies. The three main groups of
channelopathies contributing to the majority of genotype
positive patients are congenital long QT syndrome (LQTS),
catecholaminergic polymorphic ventricular tachycardia
(CPVT) and Brugada syndrome (BrS) and related phenotypes;
the less common entities being short QT syndrome (SQTS),
early repolarization syndrome (ERS) and idiopathic ventricu-
lar fibrillation (IVF).9
Cardiac channelopathies, together with cardiomyopathies,
account for a wide spectrum of genetically inherited heart
rhythm disorders, the diagnosis and management of which is
the core purpose of the multidisciplinary ‘inherited heart
disease clinics’ being established around the globe.4 With the
establishment of a strong link between genetic mutations and
life-threatening arrhythmias, andwith the availability of solid
scientific evidence for marked reduction in morbidity and
mortality by early identification and appropriate treatment of
diseased individuals, there is a pressing need for countries like
India to incorporate genetic testing into the routine manage-
ment of patients with inherited arrhythmias. This article aims
to provide an update on the diagnostic and therapeutic as-
pects of the channelopathies and to lay the foundation for a
national collaborative effort to study these relatively rare but
vastly unexplored and preventable causes of death in the In-
dian subcontinent.1. Congenital long QT syndrome (LQTS)
LQTS encompasses a heterogeneous family of disorders
characterized by delayed cardiac repolarization and a pro-
pensity to syncope and SCD.10 Torsades de Pointes (TdP), an
often self-limiting ventricular tachyarrhythmia, is the mech-
anism behind the transient syncope in affected patients. TdP,
however, has the potential to degenerate into ventricular
fibrillation and has to be treated aggressively. The estimated
prevalence of LQTS is w1:2000 in the western world.11 Heart
rate corrected QT (QTc) interval prolongation on the surface
electrocardiogram (ECG) is the hallmark feature of LQTS; but
we know that due to incomplete disease penetrance andvariable expressivity, genetically affected individuals may
have a normal ECG.12 Sixteen genes have so far been identified
as responsible for or associated with LQTS.13 The three main
genes, KCNQ1 (LQT1), KCNH2 (LQT2) and SCN5A (LQT3) ac-
count for 75% of clinically definite cases of LQTS and the
minor genes together account for another 5%. The genetic
underpinnings of about 20% of LQTS are yet to be unravelled.
LQT1 and LQT2 are caused by loss-of-functionmutations in
the genes encoding the a subunits of two different cardiac Kþ
channels, responsible for the ionic currents IKs and IKr,
respectively. Each of the types accounts for approximately
40% of genotype-positive LQTS patients.14 LQT3, on the other
hand, is caused by gain-of-function mutations of the SCN5A
gene encoding the a subunit of the cardiac Naþ channel,
causing an increase in persistent inward sodium current (INaL)
during myocardial repolarization.15 Although predominantly
of autosomal dominant inheritance, a severe recessive formof
LQTS, termed Jervell and Lange-Nielsen syndrome occurs
rarely and is associated with congenital deafness and severe
QTc prolongation.16,17 Since the identification of the three
major LQTS genes in the early to mid-90’s, not only has our
understanding of the genotypeephenotype correlations of
LQTS broadened significantly but also mutations in other
associated genes and their regulatory proteins have become
known, paving the way for genotype-specific management.
Recently, the calmodulin genes, CALM1 and CALM2, have been
discovered to play a role in the causation of an extremely se-
vere form of LQTS. QT prolongation >600 ms, T-wave alter-
nans, cardiac arrest in infancy, multiple episodes of ICD-
terminated ventricular fibrillation mostly triggered by sym-
pathetic activation, and poor response to pharmacological
and nonpharmacological interventions are observed to be the
characteristics of these mutations.18 Another interesting
revelation has been that of the influence of genetic modifiers
on disease expression in LQTS patients. For instance, common
variants in the NOS1AP gene, originally tagged in association
with variable QT interval duration in the healthy population,
have been demonstrated to be modifiers of both the QT in-
terval and the probability of symptoms in LQTS.19 Also, com-
mon variants in the 30 untranslated region of KCNQ1 have
been shown to modify disease severity in an allele-specific
manner.202. Brugada syndrome (BrS)
BrS is the best described of the loss-of-function sodium (Naþ)
channelopathies where a loss or a reduction of Naþ channel
function is caused by mutations in the SCN5A gene and its
associated proteins.21 BrS is primarily a clinical diagnosis.
Nevertheless, fourteen genes are currently implicated in the
causation of BrS and its related phenotypes and about a third
of all BrS probands exhibit genotype positivity. Some of the
newly identified but rarer genes are Naþ channel b-subunits
(SCN1B and SCN3B), L-type calcium channels (CACNA1C,
CACNB2b and CACNA2D1), glycerol-3-phophate dehydroge-
nase 1-like enzyme gene (GPD1L), KCNE3, KCNJ8, KCND3,
Ankyrin-G and MOG1.22 Very recently, the concept that BrS
is a monogenetic disease has been challenged. Indeed, an
extended genome-wide association study provided evidence
Fig. 1 e Standard 12-lead ECG showing coved ST segment and J-point elevation ‡0.2 mV followed by a negative T wave,
termed Type 1 Brugada pattern, in the right precordial leads V1 and V2.
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netic variants in the right genesmight be sufficient to produce
the signature ECG pattern.2
Syncope, polymorphic ventricular tachycardia and SCD are
the commonest manifestations of the disease. BrS is typically
diagnosed by the ECG finding of a coved ST segment and J-
point elevation 0.2 mV followed by a negative T wave,
termed Type 1 Brugada pattern, in two or more right pre-
cordial leads in a symptomatic individual with a structurally
normal heart (Fig. 1).4 Drug challenge with sodium channel
blockers such as flecainide or ajmaline is quite often used to
unmask the concealed Type 1 Brugada pattern. Also featuring
in the continuum of conduction abnormalities caused by loss-
of-function Naþ channelopathies are progressive cardiac
conduction disease, familial atrial fibrillation and sick sinus
syndrome. Although predominantly a disease of middle-aged
men, BrS spectrum of diseases have been documented in in-
fants and young children of both sexes.23 In this age group (<2
years of age), rapid wide complex (monomorphic) ventricular
tachycardia and/or prolonged conduction intervals are
frequent signs of underlying genetic aberrations.24 In contrast
to affected adults, young children rarely exhibit the typical
Type 1 Brugada pattern on their ECG.25 Fever, a commonentity
in the pediatric population as well as an established
arrhythmia trigger in BrS patients, often plays a significant
role in exposing the young patients harbouring these
channelopathies.263. Catecholaminergic polymorphic
ventricular tachycardia (CPVT)
An adrenergic-mediated disease initially described in chil-
dren, CPVT is characterized by bidirectional or polymorphic
ventricular tachycardia in a setting of physical exercise or
emotional stress.27 A Holter recording and/or an exercise
stress test quite often help to clinch the diagnosis in a youngpatient presenting with syncope or cardiac arrest and with a
normal resting ECG and normal echocardiography. CPVT is a
highly penetrant autosomal dominant disease with SCD often
being the presenting symptom; hence family screening is an
absolute prerequisite to catch disease early and to initiate
treatment. Mutations in the cardiac ryanodine receptor (RYR2)
gene are present in 55e65% of probands while cardiac calse-
questrin (CASQ2) gene mutations, inherited in an autosomal
recessive manner, account for about 2% cases.10 Both genes
are involved in the release of calcium ions from the sarco-
plasmic reticulum, for excitationecontraction coupling. Early
onset of symptoms, particularly before the age of 5, is asso-
ciated with a poor prognosis andmale carriers have a fourfold
greater risk of cardiac events than the female counterparts.4. Other channelopathies
Short QT syndrome (SQTS), a rare channelopathy, is diag-
nosed in the presence of a QTc330ms. or a QTc<360ms and
one or more of the following: a pathogenic mutation, family
history of SQTS, family history of sudden death at age 40,
survival of a VT/VF episode in the absence of heart disease.4 So
far, gain-of-function DNA variants in 3 potassium channel
genes (KCNH2, KCNQ1, KCNJ2) have been described to asso-
ciate with SQTS. Not surprisingly, loss-of-function mutations
of the same genes are responsible for LQTS variants.
Idiopathic ventricular fibrillation (IVF), as the term sug-
gests, refers to spontaneous ventricular fibrillation in patients
with structurally normal hearts, the cause of which remains
unknown after detailed cardiac and extracardiac evaluation.28
The last decade has witnessed significant revelations con-
cerning IVF and its association with early repolarization,29
SCN5A mutations,30 and with DPP6, a founder mutation
causative of a highly lethal form of familial IVF in The
Netherlands.31 With more and more information becoming
available on the plausible pathogenetic mechanisms of what
Fig. 2 e Standard 12-lead ECGs of LQTS types 1, 2 and 3. Note the prolonged QTc in all three ECGs and the broad based
prolonged T wave in LQTS type 1, low amplitudemoderately delayed T wave in type 2, and the late appearing non-distinct T
wave in type 3.
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pathophysiology of SCD is also rapidly expanding.5. The channelopathic approach to diagnosis
The key components in establishing a diagnosis of a chan-
nelopathy are a thorough evaluation of the presenting
symptom(s), systematic retrieval of the relevant historical
clues and a prudent approach to investigative procedures.
Since affected patients may first present to their family
doctors, paediatricians or neurologists, it is imperative that
all physicians and not just cardiologists are aware of and
can identify the signs of an underlying inherited cardiac
pathology.
5.1. Presenting symptom(s)
Syncope (transient loss of consciousness), resuscitated SCD
(sudden cardiac arrest requiring external defibrillation) and
SCD are the most commonly encountered symptoms in
channelopathies while palpitation, breath-holding spells,
seizure-like episodes and extracardiac findings (for example
congenital deafness) are the rarer presentations. As far as
syncope is concerned, it is considered one of the most chal-
lenging dilemmas for a clinician because on one hand, it could
be as innocent as a vasovagal syncope, and on the other as
lethal as a TdP-related syncope. Probing the circumstances
under which the syncope occurred and performing a tilt-table
test might help to differentiate the pathologies.32 Syncope is
such an integral part of neurology and cardiology practice that
several hospitals run a syncope clinic to address the needs of
patients. The circumstances of occurrence of symptoms often
serve to raise suspicion of the underlying pathology in manyof the channelopathies. Any cardiac event triggered by phys-
ical exercise, particularly swimming, is suggestive of LQT1
while that associated with sudden loud auditory stimuli such
as wake-up alarms or telephone bells are more likely to be
LQT2 related.33,34 Syncope mediated by an emotional upset,
for instance while being reprimanded by the teacher, could be
suggestive of either LQT1 or LQT2. As both physical and
emotional stimuli are physiologically linked with a catechol-
aminergic surge, it should be remembered that CPVT could
also manifest with syncope or sudden death during adren-
ergic upheavals. Events during sleep or rest are shown to be
suggestive of an SCN5A abnormality namely LQT3 or BrS.
Fever, either documented at the time of the event or
mentioned during history taking, is an important clue to a
channelopathic cause of disease, particularly loss-of-function
sodium channelopathies.
5.2. History-taking
Systematic history-taking, carried out with care for detail,
goes a long way in establishing or excluding a diagnosis of
channelopathies in an index patient.35 Apart from elaborating
on the history of presenting symptoms, the family history and
medication history have to be dealt with in length. Asking if
any family member has died suddenly and unexpectedly will
not suffice. Ideally, a pedigree chart should be drawn which
includes at least three generations. History of syncope,
palpitation, pacemaker implant, suspected seizures, recurrent
abortions, young unexplained SCD or any other cardiac diag-
nosis should be elicited in all first degree familymembers, that
is parents, siblings and offsprings in case of an adult, and in
siblings, maternal and paternal relatives and grandparents in
case the proband is a child. History of drug intake and elec-
trolyte status at the time of event occurrence is extremely
Fig. 3 e Normal resting ECG in a 38-year-old asymptomatic male sibling of a CPVT patient.
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presentation. There is a definite and clear-cut role for a nurse
specialist and a genetic counsellor, as part of the multidisci-
plinary cardiogenetic team, in the initial evaluation and sub-
sequent counselling of patients and family members.4
5.3. Electrocardiogram (ECG)
A standard 12-lead resting ECG is an integral part of evaluating
a suspected case of channelopathy. However, we have to
recognize that there are situations such as a failed resuscita-
tion setting or an intrauterine arrhythmia where a 12-lead
ECG might not be readily available but alternatives could be
utilized. A systematic scrutiny of all aspects of the ECG should
be carried out as atrial and/or ventricular depolarization and
repolarization abnormalities may coexist. Accurate mea-
surement of the conduction intervals is a definite requirement
in the evaluation of patients with suspected channelopathies.
The QT interval is measured manually from the beginning of
the QRS complex to the end of the T wave in lead II or V5. The
end of the T wave is the intersection point between the iso-
electric baseline and the tangent representing the maximal
downward slope of the positive T wave or maximal upward
slope of the negative T wave.36 Themean of three consecutive
QT intervals is calculated and QTc is obtained using the
Bazett’s formula (QT/ORR). Different repolarization patterns
on the ECG are associated with different genotypes: broad
based prolonged T wave in LQT1, low amplitude moderately
delayed T wave in LQT2, and the late appearing non-distinct T
wave in LQT3 (Fig. 2). The PR interval and QRS duration can be
prolonged in BrS-like phenotypes and should be scrutinized.
The typical coved ST segment pattern of BrS in the precordial
leads should not be missed. Any type of arrhythmia, such asatrial fibrillation, sinus bradycardia, monomorphic or poly-
morphic ventricular tachycardia, TdP and ventricular fibrilla-
tion could be the manifestation of an arrhythmia syndrome.
In patients with symptoms suggestive of channelopathies
and an apparently normal resting ECG (Fig. 3), exercise ECG,
lying-standing test, Holter ECG, or an implantable loop
recorder may provide additional clues to diagnosis. The QTc
values during recovery phase of an exercise test aid in the
diagnostic process of LQTS as well as to predict the type of
LQTS.37 The lying-standing test has also been shown to have
diagnostic value in patients with LQTS.38 The appearance of
bidirectional or polymorphic ventricular tachycardia during
exercise and the resolution of the same during the recovery
phase is a classical sign of CPVT (Fig. 4). Drug challenge with
Naþ channel blockers such as flecainide, procainamide and
ajmaline is used in better characterization of the not-so-
typical ECG signs of BrS and epinephrine provocation is used
in patients with a clinical suspicion of LQTS. Although prompt
recognition of disease and application of established in-
terventions lead to a significant reduction in mortality,
delayed diagnosis of channelopathies is not uncommon. The
most common alternative diagnoses are seizure disorder in
LQTS patients, atypical febrile seizures in pediatric patients
with fever related events, and SIDS in infants with an undi-
agnosed channelopathy who die suddenly. An elaborate
family history together with the recording of an ECG is
therefore mandatory in all patients presenting with an EEG-
negative seizure disorder, in young children with atypical
seizures during pyrexia and (if warranted) in the first-degree
family members of SIDS cases. While diagnosing patients
with a clearly prolonged QTc (>500 ms) is usually straight-
forward, challenges arisewhenQTc values lie in the normal or
borderline zone.
Fig. 4 e Exercise ECG of a 38-year-old asymptomatic male sibling of a CPVT patient showing bidirectional polymorphic
ventricular tachycardia.
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Echocardiography is a very useful tool in the evaluation of a
young symptomatic patient, particularly because an
abnormal echocardiographic examination is not expected in
the pure channelopathic spectrum of diseases and also
because the more common diagnoses of cardiomyopathies
and structural heart defects pertaining to this age group are
primarily diagnosed by imaging. Electrophysiological studies
are believed to play a role in the risk-stratification of BrS but
the findings from various studies are not confirmatory and its
role is still arguable.39
5.5. Clinical scoring systems
Clinical criteria incorporating family history, nature of
symptoms and ECG characteristics are normally used in the
initial evaluation of patients presenting with evidence of
LQTS. Based on the revised Schwartz criteria of 2011, 1 point
indicates low probability of LQTS, 1.5 to 3 points indicates
intermediate probability of LQTS, and 3.5 points indicates
high probability of LQTS.40 For patients with suspected SQTS,
the Gollob score could be a useful tool to facilitate
evaluation.41
5.6. Genetic testing for channelopathies
The evolution of genetic testing into a clinical diagnostic tool
has undoubtedly revolutionized the management of patients
with inherited arrhythmia syndromes. Advances in DNA
sequencing technology, namely next generation sequencing
platforms, have paved the way for rapid, reliable andrelatively less expensive genetic diagnostics and have also
made possible whole exome and whole genome sequencing
whereby previously undescribed genetic variants are being
identified in the causation of SCD.
While the pathogenetics of various human diseases are
beginning to unfold, LQTS is one disease where impact of
genetics is felt in at least three different areas: diagnosis, risk-
stratification and treatment.7 Genetic testing has significantly
altered the dynamics of diagnosing LQTS, especially in pa-
tients with a nondiagnostic QTc where clinical scoring loses
efficacy. In addition to the genotypeephenotype correlations
that have emerged from genetic testing of large cohorts of
LQTS patients from the International LQTS registry and a few
nationwide registries, an abundance of information has
become available on the location, type, and biophysical
function of mutations as independent risk factors influencing
the clinical course of the disorder. Age, gender, QTc, nature of
genetic mutation, and response to beta-blocker therapy, are
the five major determinants of risk of SCD in an individual
with LQTS.42 While LQT1 males are at increased risk for car-
diac events in childhood in particular, LQT2 females, probably
due to sensitivity to changes in sex hormones, experience
events mainly after the onset of adolescence or menopause
and in the postpartumperiod. Occurrence of a cardiac event in
the first year of life leaves the patient at a very high risk of
subsequent SCA/SCD during the next 10 years of life. QTc
>500 ms is a powerful indicator of risk; however, a quarter of
LQTS mutation carriers have a normal range QTc but still
exhibit a greater than 10-fold increase in life-threatening
events compared to unaffected family members.43 Com-
bined assessment of clinical and mutation specific data, such
as their site of occurrence in the ion channels, has recently
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Patients, particularly women, with intracellular cytoplasmic
loop (C-loop) missense mutations in the KCNQ1 gene exhibit a
high risk for life-threatening events, whereas among LQT2
patients, men with pore-loop KCNH2 mutations are more
prone to SCA/SCD.44
A patient with a robust clinical diagnosis of LQTS has a 75%
chance that a mutation will be found in one of the disease-
causing genes. However, genetic testing is still a time and
cost consuming tool and should not be applied without
appropriate phenotype evaluation and validation. It is
imperative that readily available tools like clinical scoring,
ECG, exercise stress test and Holter monitoring are effectively
utilised to assess the need for genotyping in all probands, as
well as in asymptomatic relatives of affected patients. As with
any clinical test, understanding the spectrum of background
noise within a given genetic test is critical to interpreting the
test results. Specifically, systematic evaluation of a genetic
test’s “signal-to-noise” ratio is crucial to determine whether a
previously unidentified variant might be the biomarker
responsible for disease or whether it is a rare genetic variant
with no relevance to the disease in question.45
For patients with BrS, genetic testing helps in confirming
the diagnosis but hardly plays any role in risk stratification
and treatment. The nature of the mutation, however, has
been proposed to be a predictor of disease severity.46 The
significance of obtaining a genetic diagnosis of loss-of-
function sodium channelopathies in preventing sudden
death among the younger relatives of affected probands has
been documented beyond doubt. In case of a clinical suspi-
cion of CPVT, genotyping for the RYR2 and CASQ2 mutations
not only has a high yield but also helps to initiate treatment
in the proband and the disease carrying family members in a
timely manner and to reduce mortality due to this highly
lethal disease.
In a family that is bereaving the unexpected death of a
young relative, post-mortem genetic testing of the stored
blood sample is the only way of identifying a channelopathic
cause of death and it also provides a lead for evaluating
family members. In case a sample is unavailable, the first-
degree relatives are interrogated and examined for any
clues to a possible cause. As most countries screen newborns
for genetic conditions with a Guthrie test, it could also serve
as a source of DNA to perform postmortem genetic testing.
However, as heelprick samples are not routinely stored long-
term, their retrieval at a later stage is not always feasible.
Comprehensive cardiac and genetic examination of relatives
of young resuscitated SCD victims has a diagnostic yield as
high as 60%.47
The role of genetic counselling in the management of pa-
tients and families cannot be overemphasized. It is the
lynchpin in obtaining a thorough family history, in providing
the pertinent information to the patients regarding the dis-
ease in question and in ensuring that both the proband and
the family members have a good understanding of what to
expect from a genetic test. An experienced counsellor also
talks to the affected persons about what could be the long-
term implications in the health front as well as in other
areas like insurability, employment and having a family of
their own for young adults.46. Treatment strategies in channelopathies
The treatment modalities employed can be largely grouped
into general preventive measures, specific lifestyle modifica-
tions, pharmacotherapy, device therapy and surgical in-
terventions. Counselling patients and parents about avoiding
drugs that are known to trigger arrhythmias (QT-prolonging
drugs and drugs to avoid in BrS), about aggressive fever
management in young children, about avoidance of compet-
itive sports in case of LQT1 and CPVT, and avoidance of loud
alarms and doorbells for LQT2 patients are some strategies
used to prevent arrhythmias. Potassium supplementation has
been proven to help control arrhythmias in LQT2 patients.
b-Blockers are the mainstay in the pharmacotherapy of
LQTS and CPVT. They represent the first choice therapy in
symptomatic LQTS patients, unless specific contraindications
exist. The impairment in the IKs current makes LQT1 patients
particularly sensitive to catecholamines and quite responsive
to b-blockade; so they seldom need more than antiadrenergic
therapy. Although b-blockers are the first-line treatment in
LQT2 and LQT3 patients as well, their risk of cardiac events
while receiving therapy (i.e. breakthrough cardiac events,
BCE), is higher than in LQT1 patients. The occurrence of BCE
has largely been attributed to a high-risk status prior to start of
therapy, noncompliance and use of other QT-prolonging
drugs. Suspicion that not all b-blockers offer equivalent pro-
tection in LQTS has been confirmed by a recent study showing
that propranolol and nadolol are the preferred choice of b-
blockers in symptomatic LQT1 and LQT2 patients.48 Pharma-
cological management of LQT3 has remained a challenge
particularly due to its high-risk profile and the relative paucity
of literature (which is closely associated with the low disease
prevalence). A large multicentre study on nearly 400 LQT3
patients supports the belief that b-blockers are generally
extremely effective in treating those LQT3 patientswho do not
have cardiac events in the first year of life.49
The cornerstone in the treatment of affected CPVT pa-
tients, both symptomatic and asymptomatic, are b-blockers.
Most symptomatic patients become symptom-free with an
adequate dosage of b-blockers but should be counselled about
the potentially lethal implications of drug noncompliance.
The second line of therapy in patients with an inadequate
response to b-blockers is flecainide, a class 1c antiarrhythmic
agent, which is usually added to the b-blocker treatment.
Device therapy and surgical denervation are reserved for the
high-risk cases where medical management is ineffective or
poorly tolerated.4 Quinidine, mexiletine and ranolazine are
the other drugs showing some promise in controlling the
inherited arrhythmias.4
Device therapy with an implantable cardioverter defibril-
lator (ICD) aborts the ventricular arrhythmias that arise in
affected patients while surgical left cardiac sympathetic
denervation (LCSD) inhibits the adrenergic overdrive medi-
ated electrical instability of the heart. In LQTS and CPVT, both
these therapies are reserved for patients with symptoms
despite b-blockers and the survivors of SCA.4 b-Blocker ther-
apy is normally continued with the adjunctive therapy, unless
contraindicated. When syncope recurs despite full dose b-
blockers, LCSD should be considered first and implemented if
Fig. 5 e Flowchart for necessary action to establish a
comprehensive approach to clinical and genetic evaluation
of patients with inherited arrhythmias in India.
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some LQT3 patients. ICD therapy, though life-saving in many
instances, has the inherent drawback of inappropriate shocks,
mechanical failures, and poor psychological impact, leading
to major setbacks in patients of all ages, more so in the pe-
diatric population. In BrS patients with a high risk of SCD, the
lack of an ideal pharmacological agent makes ICD the only
proven tool to prevent fatalities.
Prophylactic treatment in genotype-positive individuals
who have a high possibility of developing arrhythmias is one
of the major advantages of cascade screening of family
members of affected probands. ECG markers, age at diagnosis
and genotype should help guide decision to treat in asymp-
tomatic patients. It should be remembered that drug compli-
ance could be an issue in this population, particularly since a
good proportion of affected patients are in their adolescence
and would require age-appropriate counselling.7. The India perspective
With the mind-boggling developments in our understanding
of the genotypeephenotype correlations and the manage-
ment of patients with channelopathies, the fact that there is a
large lacuna in this field of medicine in India cannot be
disputed. The scope for systematic genetic analyses of cases
with a suspicious phenotype is huge given that even rare
conditions can affect a large number of people in a highly
populated country like India. Moreover, due to the unique
genetic variation of the Indian subcontinent,50 western ge-
netic data cannot be simply extrapolated to the local popula-
tion but we will have to build a database of our own. Knowing
that simple (and economical) pharmacotherapy together with
specific lifestyle changes is all that is required to prevent
sudden death in most of the affected children and young
adults, the case for genotyping of all index patients and
cascade screening of families is very strong.
The way forward is summarized in Fig. 5. There are a few
things that have to go hand in hand to be able to achieve this.First, initiation of programs to spread awareness among
general practitioners, pediatricians and neurologists and
steps to incorporate teaching on the genetics of SCD in med-
ical schools. Second, collaborative efforts among the cardiol-
ogy teams in various healthcare settings should allow for a
database to be constructed. Third, the establishment of
multidisciplinary inherited heart disease clinics should pave
the way for systematic care and counselling of affected pa-
tients and their families.
In conclusion, inherited arrhythmias are a complex set of
potentially lethal diseases, the management of which in-
cludes a thorough cardiologic evaluation, systematic genetic
diagnostics and effective therapeutic measures. The wealth of
knowledge that has become available to us from the various
registries of the western world should encourage a unani-
mous national effort to better characterize and control these
diseases in the Indian population.Conflicts of interest
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